시장보고서
상품코드
1593515

재조합 단백질 시장 규모, 점유율, 성장 분석(제품별, 용도별, 지역별) : 산업 예측(2024-2031년)

Recombinant Protein Market Size, Share, Growth Analysis, By Product (Cytokines & Growth Factors, Antibodies), By Application (Drug Discovery & Development, Biopharmaceutical Production), By Region - Industry Forecast 2024-2031

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 165 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 재조합 단백질 시장 규모는 2022년에 약 22억 달러로 평가되며, 2023년 23억 6,000만 달러에서 상승하며, 예측 기간(2024-2031년)의 CAGR은 7.2%로, 2031년에는 41억 1,000만 달러에 달할 것으로 예측됩니다.

세계 재조합 단백질 시장은 2023-2030년 상당한 CAGR(연평균 성장률)로 성장할 것으로 예상됩니다. 이러한 급격한 성장은 유전자 기술의 발전(코딩 서열의 분리, 발현 플라스미드 벡터에 대한 서열의 클로닝 등)에 기인합니다. 대부분의 치료용 재조합 단백질은 미생물, 효모, 동물 세포배양을 통해 합성되며, 단백질 간 상호 작용을 연구하는 데 필수적입니다. 재조합 단백질의 범용성은 세제, 미용 제품, 식품 보충제, 식품 제조, 진단, 백신, 치료 등 다양한 용도로 확대되고 있습니다. 시장 확대 요인으로는 의료기관의 연구개발 투자 증가, 만성질환의 유행, 바이러스 감염 방지를 위한 규제 강화 등을 꼽을 수 있습니다. 이러한 R&D 투자와 혁신적인 치료 솔루션에 대한 수요의 결합으로 시장 상황은 강력한 성장세를 보이고 있으며, 바이오테크놀러지와 의료의 진화를 활용하고자 하는 이해관계자들에게 큰 기회를 제공합니다. 시장이 성숙해짐에 따라 제품 라인업이 다양해지고, 생산 공정이 개선되고, 응용 범위가 확대되면서 재조합 단백질이 과학 연구와 치료법 개발 모두에서 매우 중요한 역할을 하고 있음이 분명해질 것입니다.

목차

서론

  • 분석 목적
  • 정의
  • 시장 범위

분석 방법

  • 정보 조달
  • 2차 데이터 소스와 1차 데이터 소스
  • 시장 규모 예측
  • 시장의 상정과 제한

개요

  • 시장 개요와 전망
  • 수급 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 역학
    • 촉진요인
    • 기회
    • 억제요인
    • 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장의 에코시스템
  • 가격 분석
  • 기술 분석
  • 밸류체인 분석
  • 특허 분석
  • 고객과 구매 기준 분석
  • 규제 분석
  • PESTEL 분석

재조합 단백질 시장 : 제품별

  • 시장 개요
  • 사이토카인·성장인자
    • 인터페론(IFN)
    • 인터류킨(IL)
    • 기타
  • 항체
  • 면역 체크포인트 단백질
  • 바이러스 항원
  • 효소
    • 키나아제
    • 대사 효소
    • 기타
  • 재조성 조절 단백질
  • 호르몬
  • 기타

재조합 단백질 시장 : 용도별

  • 시장 개요
  • Drug Discovery·의약품 개발
    • 생물학적 제제
    • 백신
    • 세포·유전자 치료
  • 연구
    • 학술연구
    • 바이오테크놀러지 연구
  • 바이오의약품 제조
  • 진단
  • 기타 용도

재조합 단백질 시장 : 숙주세포별

  • 시장 개요
  • 포유류 시스템
  • 곤충 세포
  • 효모·균류
  • 세균 세포
  • 기타 숙주세포

재조합 단백질 시장 : 최종사용자별

  • 시장 개요
  • 제약·바이오의약품 기업
  • 바이오테크놀러지 기업
  • 학술연구기관
  • CRO(임상시험 수탁기관 기관)
  • 기타 최종사용자

재조합 단백질 시장 규모 : 지역별

  • 시장 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카(MEA)
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 구도

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2023년)
  • 주요 시장 기업이 채택한 전략
  • 시장에서의 최근 활동
  • 주요 기업의 시장 점유율(2023년)

주요 기업 개요

  • Bio-Techne(미국)
  • Thermo Fisher Scientific Inc.(미국)
  • Merck KGaA(독일)
  • Danaher Corporation(미국)
  • Abnova Corporation(대만)
  • BioLegend Inc(미국)
  • Bio-Rad Laboratories, Inc.(미국)
  • BPS Bioscience, Inc.(미국)
  • Enzo Biochem Inc.(미국)
  • GenScript(중국)
  • Miltenyi Biotec B.V. & Co. KG(독일)
  • Proteintech Group, Inc.(미국)
  • Sino Biological Inc.(중국)
  • ACROBiosystems Group(미국)
  • Aviva Systems Biology Corporation(미국)
  • Sartorius CellGenix GmbH(독일)
  • Icosagen(미국)
  • Neuromics(미국)
  • ProSpec-Tany TechnoGene Ltd.(이스라엘)
  • ProteoGenix S.A.S(프랑스)
KSA 24.12.02

Global Recombinant Proteins Market size was valued at around USD 2.20 billion in 2022 and is expected to rise from USD 2.36 billion in 2023 to reach a value of USD 4.11 billion by 2031, at a CAGR of 7.2% over the forecast period (2024-2031).

The global recombinant protein market is anticipated to experience significant growth at a strong compound annual growth rate (CAGR) from 2023 to 2030. This surge is driven by advancements in genetic techniques, including the isolation of coding sequences and the cloning of these sequences into expression plasmid vectors. A majority of therapeutic recombinant proteins are synthesized using microbial, yeast, or animal cell cultures, which are essential for investigating protein-protein interactions. The versatility of recombinant proteins extends across various applications, including detergents, beauty products, food supplements, food manufacturing, diagnostics, vaccines, and therapies. Contributing factors to the market's expansion include increasing investments by healthcare organizations into research and development, a rising prevalence of chronic diseases, and a growing emphasis on regulatory measures aimed at combatting viral infections. This confluence of investments in R&D and the demand for innovative therapeutic solutions positions the recombinant protein market for robust growth and offers significant opportunities for stakeholders aiming to capitalize on the evolving landscape of biotechnology and healthcare. As the market continues to mature, we can expect to see enhanced product offerings, improved production processes, and a broader range of applications, underscoring the pivotal role recombinant proteins play in both scientific research and therapeutic development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Proteins market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Proteins Market Segmental Analysis

Global Recombinant Proteins Market is segmented by Product, Application, Host cell, End User and region. Based on Product, the market is segmented into Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILs), Others), Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes (Kinases, Metabolic Enzymes, Others), Recombinant Regulatory Proteins, Hormones, Others. Based on Application, the market is segmented into Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Biopharmaceutical Production, Research (Academic Research, Biotechnology Research), Diagnostics, and Others. Based on Host cell, the market is segmented into Mammalian Systems, Insect Cells, Yeast & Fungi, Bacterial Cells, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical, Academic Research Institutes, Contract Research Organizations, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Recombinant Proteins Market

The Global Recombinant Proteins market is propelled by rising R&D expenditures and increased funding within pharmaceutical and biotechnological sectors, leading to significant advancements in drug development. The heightened emphasis on regulatory compliance has expanded treatment options for rare diseases, such as hemophilia and bleeding disorders, further fueling market growth. The escalating demand for biopharmaceuticals is largely attributed to recombinant proteins, which offer enhanced potency, specificity, and reduced side effects compared to conventional small molecule therapies. Consequently, these factors are catalyzing the development of recombinant protein drugs targeting a diverse array of illnesses, including autoimmune disorders, infectious diseases, and cancer.

Restraints in the Global Recombinant Proteins Market

The Global Recombinant Proteins market faces significant restraints due to intense price competition resulting from an influx of key players introducing similar products in a limited market. This saturation leads to decreasing prices, which, while benefiting consumers, undermines profitability and hampers market growth. Additionally, the sector grapples with a shortage of trained medical professionals proficient in recombinant protein applications and research. This skill gap restricts innovation, development, and the effective utilization of recombinant technologies, further stifling industrial advancement. Together, these factors constrain the market's potential and hinder its ability to reach broader applications and increased revenue streams.

Market Trends of the Global Recombinant Proteins Market

The Global Recombinant Proteins market is witnessing robust growth, particularly within the antibody segment, which is anticipated to expand exponentially due to increased adoption across diverse applications such as therapeutics, diagnostics, and research. This trend is driven by advancements in biotechnology, enabling companies to efficiently identify and produce high-quality antibodies through optimized selection processes and expression systems. The rising demand for monoclonal antibodies in personalized medicine, along with a growing focus on biopharmaceuticals, is further propelling market expansion. As industries seek innovative solutions to healthcare challenges, recombinant proteins are becoming vital assets, solidifying their role in modern medicine and research.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Pricing Analysis
  • Technology Analysis
  • Value Chain Analysis
  • Patent Analysis
  • Customer & Buying Criteria Analysis
  • Regulatory Analysis
  • PESTEL Analysis

Recombinant Proteins Market, By Product

  • Market Overview
  • Cytokines & Growth Factors
    • Interferons (IFNs)
    • Interleukins (ILs)
    • Others
  • Antibodies
  • Immune Checkpoint Proteins
  • Virus Antigens
  • Enzymes
    • Kinases
    • Metabolic Enzymes
    • Others
  • Recombinant Regulatory Proteins
  • Hormones
  • Others

Recombinant Proteins Market, By Application

  • Market Overview
  • Drug Discovery & Development
    • Biologics
    • Vaccines
    • Cell & Gene Therapy
  • Research
    • Academic Research
    • Biotechnology Research
  • Biopharmaceutical Production
  • Diagnostics
  • Other Applications

Recombinant Proteins Market, By Host Cell

  • Market Overview
  • Mammalian Systems
  • Insect Cells
  • Yeast & Fungi
  • Bacterial Cells
  • Other Host Cells

Recombinant Proteins Market, By End User

  • Market Overview
  • Pharmaceutical & Biopharmaceutical Companies
  • Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations
  • Other End Users

Recombinant Proteins Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Bio-Techne (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Danaher Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abnova Corporation (Taiwan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioLegend Inc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Rad Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BPS Bioscience, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Enzo Biochem Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GenScript (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Miltenyi Biotec B.V. & Co. KG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Proteintech Group, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sino Biological Inc. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ACROBiosystems Group (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aviva Systems Biology Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sartorius CellGenix GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Icosagen (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Neuromics (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ProSpec-Tany TechnoGene Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ProteoGenix S.A.S (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제